Geron Corporation reported Q4 and full-year 2025 results, achieving $48 million in Q4 product revenue and $184 million for the full year, driven by RYTELO. The company reiterated 2026 revenue guidance and expects operating expenses to be within a range, while also implementing a workforce reduction. Geron ended the year with approximately $401 million in cash and marketable securities.
RYTELO net product revenue reached $48.0 million in Q4 2025 and $183.6 million for the full year 2025.
positiveRYTELO demand grew by 9% in Q4 2025 compared to Q3 2025.
positiveIncreased ordering accounts by 150 in Q4 2025 to approximately 1,300.
positiveEnded 2025 with approximately $401.1 million in cash, cash equivalents, restricted cash and marketable securities.
neutralReported a net loss of $31.1 million for Q4 2025 and $85.8 million for the full year 2025.
negativeTotal costs and operating expenses increased to $75.8 million in Q4 2025 and $254.7 million for the full year 2025, compared to $67.6 million and $250.7 million in the prior year periods.
negativeImplemented a workforce reduction in December 2025, representing approximately one-third of the workforce.
attentionRestructuring charges of $17.0 million were incurred in Q4 2025 due to the workforce reduction.
negativeCash, cash equivalents, restricted cash and marketable securities decreased to $401.1 million as of December 31, 2025, from $502.9 million as of December 31, 2024.
negativeMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Product Revenue | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Strategic actions taken in the second half of 2025 position Geron to drive RYTELO demand growth and invest to create value while lowering total operating expenses year-over-year.
In 2026, we are laser-focused on executing our commercial strategy.
The commercial opportunity for RYTELO in second-line lower-risk MDS is significant and supported by its FDA label, NCCN Guidelines and a growing body of scientific evidence.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.